Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,242.42 -717.70 (-1.12%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
AMGN Jun 2024 165.000 call
| Previous close | 71.05 |
| Open | 71.05 |
| Bid | 98.60 |
| Ask | 102.25 |
| Strike | 165.00 |
| Expiry date | 2024-06-21 |
| Day's range | 71.05 - 71.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
PR NewswireAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
ZacksAnalysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
